| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6221633 | SANOFI AVENTIS US | Insulin derivatives having a rapid onset of action |
Jun, 2018
(5 years ago) | |
| US7696162 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Mar, 2022
(2 years ago) | |
| US7452860 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Mar, 2022
(2 years ago) | |
| US6960561 | SANOFI AVENTIS US | Zinc-free and low-zinc insulin preparations having improved stability |
Jan, 2023
(1 year, 3 months ago) | |
Apidra is owned by Sanofi Aventis Us.
Apidra contains Insulin Glulisine Recombinant.
Apidra has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Apidra are:
- US6221633
- US7696162
- US7452860
- US6960561
Apidra was authorised for market use on 16 April, 2004.
Apidra is available in injectable;iv (infusion)-sc dosage forms.
Apidra can be used as method of treating a patient suffering from diabetes mellitus.
The generics of Apidra are possible to be released after 25 January, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: Method of treating a patient suffering from diabetes mellitus
Dosage: INJECTABLE;IV (INFUSION)-SC
APIDRA family patents
